SB 239063

structure in first source

Also Known As:

SB-239063; trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole; cyclohexanol, 4-(4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl)-, trans-

Networked: 17 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - SB 239063: 17
  - Pyrimidines: 510
    - SB 239063: 17

Experts

1.	Adams, J L: 4 articles (03/2001 - 04/2000)
2.	Barone, F C: 4 articles (03/2001 - 10/2000)
3.	Lee, J C: 4 articles (03/2001 - 04/2000)
4.	Parsons, A A: 4 articles (03/2001 - 10/2000)
5.	Willette, Robert N: 3 articles (05/2005 - 04/2002)
6.	Erhardt, J A: 3 articles (03/2001 - 02/2001)
7.	Legos, J J: 3 articles (03/2001 - 02/2001)
8.	Badger, A M: 2 articles (03/2001 - 02/2001)
9.	Hunter, A J: 2 articles (03/2001 - 02/2001)
10.	Irving, E A: 2 articles (03/2001 - 02/2001)

Related Diseases

1.	Stroke (Strokes) 03/01/2001 - "SB 239063 was administered orally pre- and post-stroke and intravenously post-stroke. " 02/16/2001 - "observed within 2 h) reductions in diffusion weighted imaging (DWI) intensity following treatment with SB 239063 correlated (r=0.74, P<0.01) to neuroprotection seen up to 7 days post stroke. " 03/01/2001 - "In both moderate and severe stroke, SB 239063 reduced infarct size by 28-41%, and neurological deficits by 25-35%. " 02/01/2001 - "In both moderate and severe stroke, intravenous SB 239063 produced a maximum reduction of infarct size by 41 and 27% and neurological deficits by 35 and 33%, respectively. " 02/01/2001 - "SB 239063 reduced infarct volume (48%) and neurological deficits (42%) when administered orally (15 mg/kg, b.i.d.) before moderate stroke. "
2.	Infarction (Infarctions) 12/01/2005 - "In the pig, SB-239063 similarly inhibited myocardial p38 activation, but there was no corresponding effect on the degree of infarction injury (43.6 +/- 4.0% vs. 41.4 +/- 4.3%). " 02/16/2001 - "Oral SB 239063 (5, 15, 30, 60 mg/kg) administered to each animal 1 h pre- and 6 h post MCAO provided significant (P<0.05) dose-related neuroprotection reducing infarct size by 42, 48, 29 and 14%, respectively. " 12/01/2005 - "Infusion of SB-239063 5 min before ischemia in the mouse prevented ischemia-induced p38 activation, resulting in a 25% reduction of infarct size compared with vehicle-treated animals (27.9 +/- 2.9% vs. 37.5 +/- 2.7%). " 03/01/2001 - "In both moderate and severe stroke, SB 239063 reduced infarct size by 28-41%, and neurological deficits by 25-35%. " 02/16/2001 - "The most effective dose (15 mg/kg) was further evaluated in detail and SB 239063 significantly (P<0.05) reduced neurologic deficit and infarct size by at least 30% from 24 h through at least 1 week. "
3.	Ischemic Stroke 03/01/2001 - "The second generation p38 MAPK inhibitor SB 239063 was identified to exhibit increased kinase selectivity and improved cellular and in vivo activity profiles, and thus was selected for evaluation in two rat models of permanent focal ischemic stroke. "
4.	Ischemia 05/01/2005 - "The purpose of this study was to test the hypothesis that acute treatment of rats with a selective p38 inhibitor, SB-239063, inhibits ischemia/reperfusion-induced leukocyte-endothelial adhesion in vivo. " 03/01/2001 - "SB 239063 also provided direct protection of cultured brain tissue to in vitro ischemia. " 02/16/2001 - "SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia." 12/01/2005 - "Infusion of SB-239063 5 min before ischemia in the mouse prevented ischemia-induced p38 activation, resulting in a 25% reduction of infarct size compared with vehicle-treated animals (27.9 +/- 2.9% vs. 37.5 +/- 2.7%). " 02/01/2002 - "In the present study, we investigated the effect of SB 239063, a specific p38 MAPK inhibitor, on myocardial injury in a murine ischemia/reperfusion (I/R) model and elucidated the mechanism by which p38 MAPK inhibitor may exert its protective effect against I/R injury. "
5.	Brain Injuries (Brain Injury) 01/01/2009 - "Significant protection after in vivo oral use of SB-239063 from brain injury and neurological deficits was observed in one study. " 02/01/2001 - "SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia." 03/01/2001 - "In addition, neuroprotective plasma concentrations of SB 239063 that reduced p38 activity following stroke also reduced the stroke-induced expression of IL-1beta and TNFalpha (i.e., cytokines known to contribute to stroke-induced brain injury). "

Related Drugs and Biologics

1.	p38 Mitogen-Activated Protein Kinases
2.	Cytokines
3.	Phosphotransferases (Kinase)
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	Lipopolysaccharides
6.	imidazole
7.	Interleukin-1beta (Interleukin 1 beta)
8.	Matrix Metalloproteinases (MMPs)
9.	Anti-Allergic Agents (Antiallergic Agents)
10.	Ovalbumin